✨ Onyx Summary Cellares announced that the FDA has cleared an IND amendment allowing Cabaletta Bio to use Cellares’ automated Cell Shuttle and Cell Q platforms to manufacture and release its investigational autoimmune CAR T therapy rese-cel, with first patient dosing expected in the first half of 2026. The clearance marks
✨ Onyx Summary Cellares has secured a long-term lease for a new European IDMO Smart Factory at Leiden Bio Science Park, establishing its European headquarters and adding regional automated manufacturing capacity. The move strengthens Cellares’ global network to support time-sensitive, patient-specific cell therapy programs with standardized, scalable production as partners advance
✨ Onyx Summary Vibrant Therapeutics raised $61 million in new financing, bringing total capital to $100 million, appointed Han Lee, Ph.D., as co-CEO, and secured FDA acceptance of the IND for its lead EGFR-targeted program VIB305. The funding and regulatory milestone position the company to expand globally, advance U.S.
✨ Onyx Summary Legend Biotech Corporation highlighted strong commercial momentum for CARVYKTI®, surpassing 10,000 patients treated globally, expanding manufacturing capacity, and securing label updates supporting overall survival benefits, while outlining plans to drive profitability in 2026. The update also underscored pipeline expansion across frontline, allogeneic, and in vivo CAR-T programs,
✨ Onyx Summary Perspective Therapeutics, Inc. outlined 2026 strategic priorities focused on advancing its targeted radiopharmaceutical pipeline, highlighted by continued dose optimization and maturing clinical data for VMT-α-NET, alongside progress in melanoma and solid tumor programs. The company also emphasized ongoing expansion of manufacturing infrastructure and anticipated clinical updates throughout 2026
EMERYVILLE, Calif., Jan. 12, 2026 – Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, provided today a corporate update and outlined its strategic priorities for 2026. “Our strong execution in 2025 solidifies our leadership position in autoimmune CAR T
✨ Onyx Summary Lexicon Pharmaceuticals, Inc. outlined multiple 2026–2027 catalysts at the J.P. Morgan Healthcare Conference, including progress in Phase 3 sotagliflozin programs for hypertrophic cardiomyopathy and type 1 diabetes, advancement of pilavapadin for neuropathic pain, and milestone-driven partnerships with Viatris and Novo Nordisk. The update highlighted a strengthened
✨ Onyx Summary Geron Corporation issued 2026 financial guidance projecting RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million, reflecting expected commercial growth alongside reduced operating spend. The outlook underscores Geron’s focus on scaling RYTELO in lower-risk MDS, advancing its Phase 3 IMpactMF
✨ Onyx Summary Ocugen, Inc. reported publication in Nature Eye of positive 12-month Phase 1 GARDian1 trial results for OCU410ST, showing favorable safety and early efficacy signals in patients with Stargardt disease, including reduced atrophic lesion growth and stabilized or improved visual acuity versus untreated eyes. The data support advancement of
✨ Onyx Summary Ocugen, Inc. announced that CEO and co-founder Dr. Shankar Musunuri will present at the J.P. Morgan Healthcare Conference on January 15, 2026, highlighting progress across its modifier gene therapy platform and its roadmap toward multiple BLA filings beginning with OCU400 for retinitis pigmentosa. MALVERN, Pa., Jan. 09,
✨ Onyx Summary Perspective Therapeutics, Inc. reported updated interim Phase 1/2a data for its lead radiopharmaceutical [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, showing no dose-limiting toxicities across 56 treated patients and encouraging anti-tumor activity at the 5.0 mCi dose. The results, presented at ASCO GI 2026, support continued dose
✨ Onyx Summary Foghorn Therapeutics Inc. outlined its 2026 strategic objectives, highlighting a $50 million equity financing that strengthens its balance sheet and supports advancement of its first-in-class oncology pipeline, including the ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers. The update underscored progress across partnered and proprietary degrader programs
✨ Onyx Summary Lexicon Pharmaceuticals, Inc. released a white paper summarizing insights from an October 2025 Washington, D.C. roundtable on chronic pain, highlighting the scale of unmet need and barriers to access for effective, non-opioid treatments. The publication aligns with recent U.S. Senate legislation aimed at expanding Medicare coverage
✨ Onyx Summary MassBio reported that Massachusetts biopharma companies grew their drug development pipeline by nearly 14% in 2025—more than double the national rate—despite venture capital falling to a six-year low and IPO markets remaining constrained. The data underscores the state’s continued strength in early-stage innovation, premium venture
✨ Onyx Summary Guardant Health, Inc. announced that its FDA-approved Shield blood test for colorectal cancer screening is now covered by TRICARE for active-duty service members and their families, with no copay for average-risk individuals aged 45 and older. The coverage expands access to the first FDA-approved blood-based primary screening option
✨ Onyx Summary Cellares and City of Hope will collaborate to evaluate automated manufacturing and quality control for City of Hope’s investigational CAR T therapy targeting glioblastoma at the preclinical stage. The effort aims to establish scalable, reproducible manufacturing processes for solid tumor CAR T programs, addressing a key bottleneck
![Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium](https://storage.ghost.io/c/89/48/8948ce11-5e2a-481d-9f95-cf8a6b32a75a/content/images/size/w1304/format/webp/2026/01/Perspective.png)
